Skip to main content
. 2018 Jan 13;9(42):26770–26786. doi: 10.18632/oncotarget.24247

Table 2. The association between clinicopathological characteristics and expression of RAB11B.

Factors No of tissues (n = 145), n (%) RAB11B expression Pb value
Low (n = 71), n (%) High (n = 74), n (%)
Age
 ≤ 20 50 (34.5) 18 (36.0) 32 (64.0) 0.023
 > 20 95 (65.5) 53 (55.8) 42 (44.2)
Gender
 Male 91 (62.8) 49 (53.8) 42 (46.2) 0.127
 Female 54 (37.2) 22 (40.7) 32 (59.3)
Location
 Tibia/femur 98 (67.6) 44 (44.9) 54 (55.1) 0.157
 Elsewhere 47 (32.4) 27 (57.4) 20 (42.6)
Histological type
 Osteoblastoma 99 (68.3) 43 (43.4) 56 (56.6) 0.051
 Else 46 (31.7) 28 (60.9) 18 (39.1)
Differentiated degree
 High/middle 52 (35.9) 36 (69.2) 16 (30.8) < 0.001
 Low/undifferentiation 93 (64.1) 35 (37.6) 58 (62.4)
TNM
 T1N0M0 26 (17.9) 10 (38.5) 16 (61.5) 0.237
 T2N0M0 119 (82.1) 61 (51.3) 58 (48.7)
Clinical stage
 I 27 (18.6) 19 (70.4) 8 (29.6) 0.014
 II 118 (81.4) 52 (44.1) 66 (55.9)

bPearson Chi-Square P value.

The expression of RAB11B is reflected by the histochemistry score(H-score).H-score is equal to Σ(pi*i), which the ‘pi’ means the percentage of RAB11B-positive cells in the section and the ‘i’ means the tint strength of the cells. And the H-score cut-off based on the median of the H-score of 145 osteosarcoma tissues and classed as low(H-score ≤ 25) or high(H-score > 25) RAB11B expression.